Fresh donor cells take on childhood leukemia in early trial
NCT ID NCT06080191
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a one-time infusion of specially engineered immune cells from a healthy donor in 24 children and young adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The main goal is to check safety and find the best dose, while also watching for signs that the cells are working. Because the cells come from another person, there is a risk of graft-versus-host disease, so the study is carefully monitoring for that.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- donor-derived CD19-targeted CAR T-cells
- What this could lead to
- If successful, this could provide a new treatment option for children with hard-to-treat leukemia who have run out of standard therapies.
- What could go wrong
- This is a very early phase 1 trial with only 24 participants, so safety and dosing are still being figured out. There are serious risks like severe immune reactions or graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ospedale Pediatrico Bambino Gesù
RECRUITINGRome, Italy, 00165, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells be engineered to fight blood cancer?
- Can a Chemo-Antibody combo beat a tough leukemia?
- Personalized chemo dosing may boost leukemia remission in kids
- Targeted drug aims to clear hidden leukemia before transplant
- Supercharged immune cells take aim at cancer and viruses in one shot
- Double-Pronged immune cells take aim at stubborn blood cancers